

1. [Nothing Special \(301\) to report](#) – Hindu Business Line

The Special 301 Report is expected to be out on or before April 30.

The author talks about why India is in the Priority Watch List category for more than 15 years. And why its status will continue as there is no demand from the pharmaceutical IP lobby to categorise India as a Priority Foreign Country.

2. [Generic drugs: The right time, right place, right price](#) – Hindustan Times

Indian generic manufacturers have been the main suppliers of affordable medicines of assured quality, leading the way by driving high performance and ramping up productive capacity. Today, India has developed a powerful and dynamic industry that is socially responsible. Innovation and high-volume manufacture has made generic medicines the pharmaceuticals of choice in the developing world.

3. [Key drivers for good health](#) – The Hindu

This month marks the introduction of the Sustainable Development Goals (SDGs), which aim to dramatically improve lives across the world by 2030. The SDGs will help countries frame their policies and strategies towards achieving these mutually agreed upon goals and targets. SDG 3, which aims to ensure good health for all, is a priority for India.

4. [Top American Business Group Seeks Clarity In India's Compulsory License Policy](#) – NDTV

The (US India Business) Council and its members seek transparency, consistency and clarity in the legislation and circumstances under which such compulsory licenses can be issued so as to enable well-informed business decisions. The recent statement from the trade advocacy group comes after recent reports on the USIBC's submission to the United States Trade Representative (USTR) on India's stance on compulsory licensing.

1. [Nothing Special \(301\) to report](#) – Hindu Business Line

2. [Generic drugs: The right time, right place, right price](#) – Hindustan Times

3. [Key drivers for good health](#) – The Hindu

4. [Top American Business Group Seeks Clarity In India's Compulsory License Policy](#) – NDTV

5. [NPPA clarifies on implementation of prices fixed and notified under provisions of DPCO, 2013](#) – Pharmabiz

6. [Antimicrobial resistance poses serious consequences: J P Nadda](#) – Economic Times

7. [12 Asia Pacific countries join hands to deal with antibiotic resistance](#) - DNA

8. ['Made in India' stents going global](#) – Hindu Business Line

9. [USFDA issues draft guidance on data integrity and cGMP to reliable & appropriate data from pharma cos](#) -Pharmabiz

10. [Indian companies get USFDA nod for 14 1st-time generic drugs in 2015](#) – DNA

11. [Workshop on IPR](#) – The Hindu

12. [Public healths in the infirmary](#) – Hindu Business Line

13. [Pharma firms clear FDC stocks](#)- Times of India

14. [Right man, right time, right place – Ramachandran](#) – The Hindu

15. [Bihar to ban supply of medicinal drugs with alcohol content](#) – Times of India

16. [Roche Sues Intas Pharma Over Mircera Anaemia Drug Patent](#) – Economic Times

17. [Eli Lilly to unveil new drug every year](#) – The Hindu

5. [NPPA clarifies on implementation of prices fixed and notified under provisions of DPCO, 2013](#)

– Pharmabiz

The National Pharmaceutical Pricing Authority (NPPA) has clarified on implementation of prices fixed and notified under provisions of DPCO, 2013 and also on recalling or re-labelling or re-stickering on the label of container or pack of released stocks in the market prior to date of notifications.

The NPPA's clarification comes in the backdrop of the fact that it has in the recent past received some queries from drug manufacturers, industry associations, drugs distributors and dealer associations, etc. in respect of captioned matter. There is also some misinformation as regards recalling or re-labelling or re-stickering on the label of container or pack of released stocks in the market prior to date of notifications.

6. [Antimicrobial resistance poses serious consequences: J P Nadda](#) – Economic Times

Antibiotics resistance and failure to tackle infections "undermine" advancements that have been made in surgery and medicine, said Nadda, while delivering the ministerial address at the Asian Health Ministers' meeting on Antimicrobial resistance. He underlined the need to regulate the availability of drugs to tackle it.

Also appeared in [Business Standard](#), [DNA](#), [Financial Express](#)

7. [12 Asia Pacific countries join hands to deal with antibiotic resistance](#) – DNA

Health ministers from as many as 12 countries of the region agreed to improve the way information on antimicrobial resistance is collected and shared to guide effective policies and actions; to strengthen and harmonize how they regulate the production, sale and use of antibiotics and other antimicrobial medicines; and to take innovative approaches to stimulate research and development of new antibiotics, diagnostic tests, vaccines and other technologies, a statement issued on the Tokyo meeting of health ministers on Antimicrobial Resistance said.

8. [‘Made in India’ stents going global](#) – Hindu Business Line

At the last Transcatheter Cardiovascular Therapeutics (TCT) meeting there was appreciation for Indian stents being very effective in diabetics. TCT is a global educational meet for interventional cardiologists. The stent pricing in the country will be standardized once it's listed as an essential drug by the government and MRP is fixed.

These were some of the significant observations made at the National Intervention Council — a forum for practitioners of interventional cardiology & the interventional arm of the Cardiology Society of India being held in Hyderabad.

9. [USFDA issues draft guidance on data integrity and cGMP to reliable & appropriate data from pharma cos](#) –Pharmabiz

The US FDA has issued new draft guidance to ensure that data from pharmaceutical companies are reliable and appropriate. The move by the global regulatory authority comes after apprehensions on data integrity issues not just in India but China and other countries.

The new guidance has answers to 18 questions about data integrity, together with aspects of current good manufacturing practice (cGMP). In an age where use of information technology is ubiquitous, the guidance also highlights workflows on computers which need to be validated along with creation of electronic master production and control records (MPCR) which can only be used by authorised personnel.

10. [Indian companies get USFDA nod for 14 1st-time generic drugs in 2015](#) – DNA

Indian pharma firms accounted for 14 of total 90 first-time generic drug approvals granted by the United States Food and Drug Administration in 2015. In her message for the Office of Generic Drugs (OGD) Annual Report 2015, Director Kathleen Uhl said: "...2015 marked the highest number of generic drug approvals and tentative approvals ever more than 700".

11. [Workshop on IPR](#) – The Hindu

The Union Ministry of Commerce and Industry and Salem Productivity Council will jointly organise a day long workshop on “Intellectual Property Rights” in the city on April 23. S. Govindan, secretary of Salem Productivity Council, has said in a press release that IPR has become the need of the hour. Intellectual Property protection is critical to fostering innovation.

12. [Public healths in the infirmary](#) – Hindu Business Line

Those at the helm of policymaking in the country have been, for some time, strongly advocating austerity as the principle for public expenditure policies, particularly for the social sectors. The budgetary allocation for health and allied reveals a much wider hold of such perceptions as articulated by Panagariya.

13. [Pharma firms clear FDC stocks](#)- Times of India

With the interim stay on the ban on fixed dose combination drugs (FDC) in place till the Delhi high court hears the matter on April 18, Gujarat-based pharmaceutical companies have been able to clear a sizable part of the drugs stocks that piled up following the ban.

14. [Right man, right time, right place – Ramachandran](#) – The Hindu

As fields in Science and Technology go, the two buzzing ones, namely biotechnology and information technology have been the “newbies.” Started just about 35-40 years ago, these two have captured both the best minds and the best market. And India, happily enough, has contributed both to the science and the technology in these two fields.

15. [Bihar to ban supply of medicinal drugs with alcohol content](#) – Times of India

Bihar government is contemplating to restrict the supply of all medicinal drugs with have alcohol contents. In principal it has been decided to completely restrict its supply in Bihar in view of the huge recovery of banned cough syrups like 'Corex' from bordering Araria district couple of days back.

16. [Roche Sues Intas Pharma Over Mircera Anaemia Drug Patent](#) – Economic Times

Swiss biotechnology giant Roche has sued Ahmedabad-based drug maker Intas Pharmaceuticals in Delhi High Court, alleging infringement of its patent rights over Mircera, an injectable brand used to treat patients with anaemia in chronic kidney-related ailments.

Roche has sought an injunction order against the brand launched by Intas, but no decision has been taken yet, people familiar with the matter in legal circles said. Roche had close to \$500 million in global sales for its Mircera brand, reports suggest. Intas confirmed to ET about the Mircera case, adding it is contending a non-infringing stand on its product.

17. [Eli Lilly to unveil new drug every year](#) – The Hindu

Eli Lilly and Company (India) Pvt. Ltd. Managing Director Edgard Olaizola said: “About 50 drugs are under various stages of trials out of which seven are undergoing phase three of clinical trials. It is difficult to say which drug will be released when as we have to get regulatory/agencies’ approvals. We will roll out a diabetic drug by the year end and an oncology drug next year.”